Understanding why some patients with blood cancers don't respond to interferon-alpha treatment
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells - Diversity Supplement
This study is looking at how certain blood cancer stem cells with CALR mutations react to a treatment called interferon-alpha, to help understand why some patients improve in their blood counts but not in tumor size, which could lead to better treatments for people with blood cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11180710 on NIH RePORTER |
What this research studies
This research investigates how certain blood cancer stem cells, particularly those with CALR mutations, respond to interferon-alpha therapy. By analyzing blood samples from patients, the study aims to uncover the molecular mechanisms that lead to therapy resistance. The researchers will use advanced techniques to examine the genetic and cellular changes in these stem cells before and after treatment, providing insights into why some patients see improvements in blood counts but not in tumor size. This could help tailor more effective treatments for patients with myeloproliferative neoplasms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms who have CALR mutations and are undergoing interferon-alpha treatment.
Not a fit: Patients without CALR mutations or those not receiving interferon-alpha therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with myeloproliferative neoplasms, enhancing their response to interferon-alpha therapy.
How similar studies have performed: Previous research has shown that understanding the genetic basis of therapy resistance can lead to significant advancements in treatment, suggesting that this approach has the potential for success.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Nam, Seung Ha — Weill Medical Coll of Cornell Univ
- Study coordinator: Nam, Seung Ha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.